25.01.2018 22:01:00
|
Omnicell to Release Fourth Quarter 2017 Earnings Results on February 1, 2018
MOUNTAIN VIEW, Calif., Jan. 25, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, February 1, 2018, to discuss the Company's Fourth Quarter 2017 financial results.
What: | Omnicell Fourth Quarter 2017 earnings conference call and webcast |
When: | February 1, 2018, 1:30 p.m. PT |
Who: | Randall Lipps, chairman, president and chief executive officer |
Where: | The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 3791479.The webcast can be accessed at: http://ir.omnicell.com/events.cfm. |
How: | Link to the Omnicell website 15 minutes prior to the call to download necessary audio software. |
Replay: | Available starting at 4:30 p.m. PT on February 1, 2018, through 11:59 p.m. PT on March 15, 2018. Dial 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # 3791479. |
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.
Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.
Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.
Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.
For more information about Omnicell, Inc. please visit www.omnicell.com.
OMCL-E
View original content with multimedia:http://www.prnewswire.com/news-releases/omnicell-to-release-fourth-quarter-2017-earnings-results-on-february-1-2018-300588428.html
SOURCE Omnicell, Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Omnicell Inc.mehr Nachrichten
22.01.25 |
Erste Schätzungen: Omnicell veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
21.01.25 |
NASDAQ Composite Index-Papier Omnicell-Aktie: So viel Gewinn hätte ein Omnicell-Investment von vor einem Jahr abgeworfen (finanzen.at) | |
14.01.25 |
NASDAQ Composite Index-Wert Omnicell-Aktie: So viel Gewinn hätte ein Omnicell-Investment von vor 10 Jahren abgeworfen (finanzen.at) | |
07.01.25 |
NASDAQ Composite Index-Papier Omnicell-Aktie: So viel hätten Anleger an einem Omnicell-Investment von vor 5 Jahren verloren (finanzen.at) | |
31.12.24 |
NASDAQ Composite Index-Papier Omnicell-Aktie: So viel Verlust hätte ein Investment in Omnicell von vor 3 Jahren bedeutet (finanzen.at) | |
24.12.24 |
Pluszeichen in New York: NASDAQ Composite klettert zum Handelsende (finanzen.at) | |
24.12.24 |
Zuversicht in New York: NASDAQ Composite-Anleger greifen am Nachmittag zu (finanzen.at) | |
24.12.24 |
Freundlicher Handel: NASDAQ Composite-Anleger greifen am Dienstagmittag zu (finanzen.at) |
Analysen zu Omnicell Inc.mehr Analysen
Aktien in diesem Artikel
Omnicell Inc. | 41,20 | 0,49% |